Cepheid appears in FDA 510(k) records as the applicant for four substantially equivalent decisions dated between September 25 and October 30, 2026. The records cover two respiratory tests and one hemorrhagic fever panel, with the Xpert Xpress CoV-2/Flu plus name appearing on two separate clearances. The filings list a Sunnyvale, California address and classify the devices in Class II. [1][2][3][4]

Respiratory test clearances

Xpert Respiratory Panel received a substantially equivalent decision on September 25, 2026 under K261336, with the application received April 23, 2026. The record lists product code QOF, regulation number 866.3981 and a Traditional clearance type. The associated openFDA device name is a multi-target respiratory specimen nucleic acid test including SARS-CoV-2 and other microbial agents, in Class II under Microbiology. [4]

Xpert Xpress CoV-2/Flu plus appears twice. K263120 was received September 4, 2026 and decided October 2, 2026; K263333 was received September 22, 2026 and decided October 22, 2026. Both carry product code QOF, regulation number 866.3981, a Special clearance type and a substantially equivalent decision, with the same multi-target respiratory device name and Microbiology specialty. [2][3]

Hemorrhagic fever panel

Xpert Hemorrhagic Fever Panel was cleared under K262971, received August 26, 2026 and decided October 30, 2026. The record lists product code QVR, regulation number 866.4000, a Traditional clearance type and the openFDA device name multiplex nucleic acid detection system for biothreat agents, in Class II with an Immunology advisory committee. [1]

Cepheid's published page for the panel describes on-demand, random-access testing and sample processing that includes viral inactivation to support safer handling, citing an FDA 510(k) decision summary for a different submission number. The page also links the test within a TB and emerging infectious diseases menu alongside Xpert Mpox. [6]

A WHO Emergency Use Listing public assessment report for the Xpert Hemorrhagic Fever Panel, EUL 14508-070-00, records an outcome of Accepted, dated September 30, 2026, version 1.0. The accompanying instructions for use carry revision A, effective 2026-09, described as an initial release for WHO EUL, for use with the GeneXpert Dx System. [7][8]

How the records relate

The four linked records all sit in the 510(k) pathway with substantially equivalent decisions, and the collection's decision counts show four SESE outcomes. The smaller record sample of four entries shows the same four SESE outcomes, so the sample and the collection coincide in this snapshot; these counts describe the linked filings only, not company sales, total portfolio or safety performance. [1][2][3][4]

Cepheid is the applicant named on each record, with the Sunnyvale address appearing as a filing address rather than a verified headquarters. The records do not establish ownership, parentage or commercial availability, and no recall entries appear in the linked sample. [1][2][3][4]